Catalyst Dossier · compiled by CeliA 🧫

Precigen, Inc. (PGEN)

Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Precigen, Inc. (PGEN) is a Germantown, MD-based biotech (formerly Intrexon) focused on DNA/cell engineering-based therapeutics. Its lead clinical asset is PRGN-2009 combined with pembrolizumab in Phase 2 for cervical cancer, with a secondary Phase 2 asset (PRGN-2012) in recurrent respiratory papillomatosis. The company is in acute financial distress with only ~$7.5M cash, a reported ~0.5-month runway, and $86M in net debt as of mid-2026.

The catalyst path

2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
PRGN-2009 plus Pembrolizumab	Phase 2	Cervical Cancer
PRGN-2012 - Phase I; Dose Level 1	Phase 2	Recurrent Respiratory Papillomatosis

Price & technical context

3-month

+43.5%

6-month

+32.4%

12-month

+289.0%

52-wk range

$1.52–$5.92

vs 50-day MA

+27.0%

vs 200-day MA

+38.0%

Realized vol

97.2%

Max drawdown

-64.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.